Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02519270 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
A Phase 1 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02519270: Clinical Trial Phase 1 study, sponsored by Spectrum Pharmaceuticals.
NCT02519270 is a Phase 1 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02519270, a Phase 1 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
Primary Outcome
Adverse Event collection and assessment will be done for all potentially treated subjects to assess the safety, tolerability, and determine the maximum tolerated dose
Interventions
- BIOLOGICAL IGN002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 1 |
Why NCT02519270 stopped before completion
NCT02519270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which IGN002 is the first listed.
NCT02519270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02519270 about?
NCT02519270 is a clinical study titled "Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects". A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
What is the current status of trial NCT02519270?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-05-01. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT02519270?
The interventions under investigation include: IGN002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02519270?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02519270's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI